Cardio Diagnostics Holdings (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection

Questions around this news

What is coronary heart disease?
Coronary heart disease (CHD) occurs when the blood vessels supplying the heart become narrowed or blocked, limiting blood flow to the heart muscle. It can lead to chest discomfort, a heart attack, or other complications. The release identifies CHD as a major cause of death in the United States.
What does sensitivity mean when evaluating a risk calculator?
Sensitivity describes how well a test or screening method identifies people who have the condition it is intended to detect. A method with low sensitivity may fail to flag some people who do have the condition. Sensitivity is one measure of performance and does not, by itself, show how accurately a positive result identifies people who have the condition.
How does the company describe its molecular approach to heart disease testing?
The release says the company has developed clinical tests based on genetics and epigenetics. It describes these fields as examining genes and how they are expressed and regulated at the molecular level. It does not provide further details about how the tests are performed or how their results are used in patient care.

For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops.
What makes CHD numbers particularly troubling is that so much of this is preventable.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level.

Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means that many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.

For decades, cardiovascular risk assessment has centered on a checklist. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full…

At a glance

Company: Cardio Diagnostics Holdings
Ticker: NASDAQ: CDIO

Key figures

Individuals with CHD without traditional risk factors: approximately 50%
Average sensitivity of conventional risk calculators: 39%

Products and programs

Clinical tests rooted in epigenetics and genetics

SEC filings

Earlier from Cardio Diagnostics Holdings

Back to News Center